<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Bendamustine</id>
	<title>Bendamustine - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Bendamustine"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Bendamustine&amp;action=history"/>
	<updated>2026-05-11T11:38:44Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Bendamustine&amp;diff=5831605&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Bendamustine&amp;diff=5831605&amp;oldid=prev"/>
		<updated>2024-05-27T01:32:36Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:Bendamustine2DCSD.svg|thumb|Bendamustine2DCSD|right]] [[File:Figure 4 (8530146434).png|thumb|Figure 4 (8530146434).png]] &amp;#039;&amp;#039;&amp;#039;Bendamustine&amp;#039;&amp;#039;&amp;#039; is a [[chemotherapy]] medication used in the treatment of certain types of [[cancer]]. It is classified as an [[alkylating agent]] and is primarily used to treat [[chronic lymphocytic leukemia]] (CLL) and [[non-Hodgkin lymphoma]] (NHL). Bendamustine is known for its unique mechanism of action, which combines properties of both alkylating agents and [[antimetabolites]].&lt;br /&gt;
==Medical Uses==&lt;br /&gt;
Bendamustine is indicated for the treatment of:&lt;br /&gt;
* [[Chronic lymphocytic leukemia]] (CLL)&lt;br /&gt;
* [[Non-Hodgkin lymphoma]] (NHL), particularly in patients who have not responded to other treatments&lt;br /&gt;
==Mechanism of Action==&lt;br /&gt;
Bendamustine works by causing [[DNA]] damage in cancer cells, which leads to cell death. It forms cross-links between DNA strands, preventing the cancer cells from dividing and growing. This dual mechanism of action, involving both alkylation and antimetabolite activity, makes bendamustine effective against cancer cells that may be resistant to other treatments.&lt;br /&gt;
==Administration==&lt;br /&gt;
Bendamustine is administered intravenously. The dosage and treatment schedule depend on the type of cancer being treated, the patient&amp;#039;s overall health, and other factors. It is typically given in cycles, with periods of treatment followed by periods of rest.&lt;br /&gt;
==Side Effects==&lt;br /&gt;
Common side effects of bendamustine include:&lt;br /&gt;
* [[Nausea]]&lt;br /&gt;
* [[Vomiting]]&lt;br /&gt;
* [[Fatigue]]&lt;br /&gt;
* [[Fever]]&lt;br /&gt;
* [[Infections]] due to lowered white blood cell counts&lt;br /&gt;
* [[Anemia]]&lt;br /&gt;
* [[Thrombocytopenia]]&lt;br /&gt;
Serious side effects can include severe infections, allergic reactions, and secondary cancers.&lt;br /&gt;
==History==&lt;br /&gt;
Bendamustine was first synthesized in the 1960s in the former [[East Germany]]. It was approved for medical use in the United States by the [[Food and Drug Administration]] (FDA) in 2008.&lt;br /&gt;
==Research==&lt;br /&gt;
Ongoing research is exploring the use of bendamustine in combination with other chemotherapy agents and targeted therapies to improve outcomes for patients with various types of cancer.&lt;br /&gt;
==See Also==&lt;br /&gt;
* [[Chemotherapy]]&lt;br /&gt;
* [[Chronic lymphocytic leukemia]]&lt;br /&gt;
* [[Non-Hodgkin lymphoma]]&lt;br /&gt;
* [[Alkylating agent]]&lt;br /&gt;
* [[Antimetabolite]]&lt;br /&gt;
==References==&lt;br /&gt;
{{Reflist}}&lt;br /&gt;
==External Links==&lt;br /&gt;
{{Commons category|Bendamustine}}&lt;br /&gt;
[[Category:Chemotherapy]]&lt;br /&gt;
[[Category:Alkylating agents]]&lt;br /&gt;
[[Category:Antineoplastic drugs]]&lt;br /&gt;
[[Category:Leukemia]]&lt;br /&gt;
[[Category:Lymphoma]]&lt;br /&gt;
[[Category:1960s introductions]]&lt;br /&gt;
{{medicine-stub}}&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>